Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07160738 · ClinicalTrials.gov registry record · Phase 1
A Study to Learn About How the Study Medicines Called Itraconazole and Probenecid Change How the Body Processes PF-07220060
A Phase 1 study of Healthy Adults, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT07160738 is a Phase 1 study of Healthy Adults that is actively recruiting participants, run by Pfizer. The registered enrollment target is 28 participants, below the 86-participant average among 33 other Healthy Adults trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07160738, a Phase 1 study of Healthy Adults, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to see and learn the effect of multiple doses of a strong CYP3A4 inhibitor and a potent UGT2B7 inhibitor on the PK of PF-07220060.
Conditions Studied
Interventions
- DRUG PF-07220060
- DRUG Itraconazole
- DRUG Probenecid
Study Locations (1)
Connecticut
- Pfizer Clinical Research Unit - New Haven - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2025-09-22 |
| Est. Completion | 2026-01-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07160738
The ClinicalTrials.gov registry entry for NCT07160738 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 86-participant average among 33 other Healthy Adults trials with a reported enrollment target (67% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Adults appearing as the primary indexed condition, and to 3 interventions - of which PF-07220060 is the first listed.
NCT07160738 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT07160738 about?
NCT07160738 is a clinical study titled "A Study to Learn About How the Study Medicines Called Itraconazole and Probenecid Change How the Body Processes PF-07220060". The purpose of the study is to see and learn the effect of multiple doses of a strong CYP3A4 inhibitor and a potent UGT2B7 inhibitor on the PK of PF-07220060.
What is the current status of trial NCT07160738?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2025-09-22. Estimated completion is 2026-01-09.
What conditions does trial NCT07160738 study?
This clinical trial studies the following conditions: Healthy Adults.
What interventions are being tested in trial NCT07160738?
The interventions under investigation include: PF-07220060 (DRUG), Itraconazole (DRUG), Probenecid (DRUG).
Who is sponsoring clinical trial NCT07160738?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07160738 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Adults
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of EDG-15400 in Healthy Adults
RECRUITING · Phase 1
-
Phase 1a Single Ascending Dose Study of MIB-725 in Healthy Adults
RECRUITING · Phase 1
-
Safety and Efficacy of Injectable Klotho Plasmid Gene Therapy in Humans
RECRUITING · Phase 1
-
Tracing the Metabolic Flux of Orally Administered NAD+ Precursors
RECRUITING · Phase 1
-
The Dose Response of Prednisone on Biochemical and Clinical Makers in Adult Healthy Volunteers
COMPLETED · Phase 1
-
A Study to Determine the Effect of KP-001 on Metformin and Midazolam Pharmacokinetics and the Effect of Clarithromycin on KP-001 Pharmacokinetics in Healthy Adult Participants
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.